FPAS
PJP icon

Focus Partners Advisor Solutions’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Focus Partners Advisor Solutions’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Buy
2,077
+1
+0% +$106 ﹤0.01% 1127
2025
Q4 		$217K Buy
+2,076
New +$209K ﹤0.01% 999
2025
Q2 		– Sell
-2,401
Closed -$208K – 1154
2025
Q1 		$208K Buy
+2,401
New +$205K ﹤0.01% 900

Other funds holding PJP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAM
Peak Asset Management Louisville, Colorado $567M AUM 16.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CI
Cavalier Investments Alpharetta, Georgia $3.7B AUM 51.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Focus Partners Advisor Solutions's PJP Position: Q1 2026 in Review

Focus Partners Advisor Solutions increased its Invesco Pharmaceuticals ETF (PJP) stake by 0.05% in Q1 2026, buying an estimated $106 and bringing the position to 2,077 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1127.

Focus Partners Advisor Solutions first reported a position in PJP in Q1 2025 and has held it in 3 quarters since. The position peaked at $217K in Q4 2025. 119 funds tracked by Wall St. Rank hold PJP as of Q1 2026.

  • Focus Partners Advisor Solutions held 2,077 shares of Invesco Pharmaceuticals ETF worth $216K as of Q1 2026.
  • Focus Partners Advisor Solutions bought 1 Invesco Pharmaceuticals ETF share in Q1 2026, an estimated $106.
  • Invesco Pharmaceuticals ETF made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #1127 holding.
  • Focus Partners Advisor Solutions first reported a position in Invesco Pharmaceuticals ETF in Q1 2025 and has held it in 3 quarters since.
  • Focus Partners Advisor Solutions's Invesco Pharmaceuticals ETF position peaked at $217K in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.